Keywords: Pfizer, Biotica Technology, Rapamycin, Neuro-inflammatory diseases

Pfizer returns worldwide rights to rapamycin analogue program to Biotica

Article | 05 August 2011

Print This

Privately-held UK biotech firm Biotica Technology says that it has regained full rights from global drugs behemoth Pfizer (NYSE: PFE) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in